Ifosfamide in the Treatment of Lung Cancer

Contributions to Oncology
Beiträge zur Onkologie

Vol. 35

Series Editors
J. H. Holzner, Vienna; W. Queißer, Mannheim

KARGER

Basel • München • Paris • London • New York • New Delhi • Bangkok • Singapore • Tokyo • Sydney

Satellite Symposium of the 19th German Cancer Congress,
Frankfurt/Main, February 28, 1988

Ifosfamide in the Treatment of
Lung Cancer

Volume Editor
D. K. Hossfeld, Hamburg

28 figures and 44 tables, 1989

KARGER
Basel • München • Paris • London • New York • New Delhi • Bangkok • Singapore • Tokyo • Sydney

Contributions to Oncology
Beiträge zur Onkologie

Drug Dosage
The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved.
Contents

Preface VII

McVie, J.G. (London); van Zandwijk, N. (Amsterdam), for the EORTC Lung Cancer Group: EORTC Lung Cancer Trials 1

Small Cell Lung Cancer


Gatzemeier, U.; Heckmayr, M.; Neuhauss, R (Hamburg): Chemotherapy of Small Cell Lung Cancer with 4-Epirubicin, Ifosfamide and Vindesine 28

Voigtmann, R.; Burghardt, F.; Nauen, P.; Sorge, B. (Herne): Combined Adriamycin/Ifosfamide Chemotherapy in Advanced Small Cell Lung Cancer .... 33

Thatcher, N.; Lind, M.J.; Anderson, H.; Steward, W.P.; Barber, P.V.; Stout, R.S.; Carroll, K.B. (Manchester): The Manchester Experience with Ifosfamide and Mesna in Lung Cancer 42

Postmus, P.E.; Splinter, T.A.W.; McVie, J.G.; Dalesio, O.; Kirkpatrick, A. (Groningen), and the EORTC Lung Cancer Cooperative Group: Standard Combination Chemotherapy versus Two Carboplatin-Containing Regimens in Small Cell Lung Cancer: A Randomized Phase II Study. Preliminary Results 51


Trillet, V. (Lyon): Combination Chemotherapy and Hyperfractionated Large-Field Radiotherapy for Limited Small Cell Lung Cancer 61

Lange, O.F.; Scheef, W.; Haase, K. D. (Bonn): Concurrent Chemo-Radiotherapy in Oat Cell Lung Cancer 66
Non-Small Cell Lung Cancer

Goerg, R.; Klasen, H.; Häßler, R.; Dannhäuser, J. (Marburg): Two Multicenter
Randomized Trials for Treatment of Non-Resectable Non-Small
Cell Lung Cancer 77

Sculier, J.P.; Klastersky, J. (Bruxelles): A Phase I Study with an Ifosfamide, Carboplatin
and Etoposide Regimen in Advanced Non-Small Cell Lung Cancer:
An Interim Analysis 85

Drings, P.; Djawid, N.; Bülzebruck, H.; Meier-Schwickerath, E.; Tessen, H.W.
(Heidelberg): Chemotherapy of Advanced Non-Small Cell Lung Cancer with
Ifosfamide and Vindesine 91

Ifosfamide, Vincristine, Fluorouracil, and Procarbazine Combination Chemotherapy
in Non-Small Cell Lung Cancer 103

Rüger, I.; Schroeder, M.; Purea, H.; Westerhausen, M. (Duisburg): Ifosfamide,
Mitomycin C and Vindesine Adapted to the Performance Status in Disseminated
Non-Small Cell Lung Cancer 106

R. (Hamburg): Mitomycin C/Ifosfamide vs. Mitomycin C/Vindesine
vs. Cisplatinum/Etoposide in Advanced Non-Small Cell Lung Cancer.
A Prospective Randomized Trial 108

van Zandwijk, N.; ten Bokkel Huinink, W.W.; Wanders, J.; Simonetti, G.; Dubbelman,
R; Franklin, H.; Brouwer, M.; McVie, J.G. (Amsterdam): Dose-Finding
Studies with Carboplatin, Ifosfamide, Etoposide and Mesna in Non-Small
Cell Lung Cancer 119

Salerno, V.; Marangolo, M. (Ravenna): Cisplatinum/VP-16 Alternating with
Ifosfamide/Vindesine and Radical Radiotherapy in Advanced Non-Small
Cell Lung Cancer 122

Garcia Girón, C.; González Barón, M.; Ordóñez Gallego, A.; Felin Batlle, J.;
Sánchez Durán, A. (Madrid): Phase II Trial in Advanced Non-Small Cell Lung
Cancer with Ifosfamide, Mitomycin and Cisplatinum 127

Rosell, R.; Abad-Esteve, A.; Moreno, I.; Barnadas, A.; Fernandez-Marcial, C.; Ribas
Mundo, M. (Barcelona): A Randomized Comparison of Two Vindesine-plus
Cisplatinum-Containing Regimens With The Addition of Mitomycin or
Ifosfamide in Patients with Non-Small Cell Lung Cancer 139

Drings, P. (Heidelberg): Summary of the Non-Small Cell Lung Cancer Session 146
Preface

It appeared both useful and interesting to organize a symposium on “Ifosfamide in the Treatment of Lung Cancer” on occasion of the 19th German Cancer Congress in Frankfurt in February 1988. It was useful because such an activity has not been attempted before although Ifosfamide is one of the most widely used drugs for the treatment of patients with lung cancer, and it was interesting because it allowed a ad hoc comparison of the experiences of an impressive number of national and international groups. This volume contains selected oral and poster contributions presented at this symposium. As the reader goes through the volume, she/he will realize that Ifosfamide is undoubtedly among the most active drugs against lung cancer; however, results in both non-small as well as small cell lung cancer are far from being satisfactory.

The organizers of the symposium wish to thank all colleagues who actively participated in the symposium and who contributed to this volume. This volume is dedicated to Prof. C. G. Schmidt who pioneered medical oncology in Germany.